Filiou Michaela D
Max Planck Institute of Psychiatry, Munich, Germany.
Proteomics Clin Appl. 2015 Oct;9(9-10):885-8. doi: 10.1002/prca.201400144. Epub 2015 Apr 2.
Despite major advances in infrastructure and instrumentation, proteomics-driven translational applications have not yet yielded the results that the scientific community has envisaged. In this viewpoint, the perspective of proteomics-based diagnostics in the field of clinical psychiatry is explored. The challenges that proteomics faces in the context of translational approaches are outlined and directions toward a successful clinical implementation are provided. Additional challenges that psychiatric disorders pose for clinical proteomics are highlighted and the potential of proteomics-based, blood tests for psychiatric disorders is being assessed. Proteomics offers a valuable toolkit for clinical translation that needs to be handled in a pragmatic manner and with realistic expectations.
尽管在基础设施和仪器设备方面取得了重大进展，但蛋白质组学驱动的转化应用尚未产生科学界所设想的结果。在本文观点中，探讨了临床精神病学领域基于蛋白质组学的诊断前景。概述了蛋白质组学在转化方法背景下面临的挑战，并提供了成功临床应用的方向。强调了精神疾病给临床蛋白质组学带来的其他挑战，并评估了基于蛋白质组学的血液检测在精神疾病诊断中的潜力。蛋白质组学为临床转化提供了一个有价值的工具包，需要以务实的方式和现实的期望来运用。
